Sygnature Discovery Ltd. and Ube Corp. have established a collaboration on a hit-to-lead program to identify SHP2 degraders. The aim is to develop potent bifunctional compounds with excellent ADME and pharmacokinetic properties for efficient degradation of SHP2, a tyrosine-specific phosphatase implicated in human cancers.